RA CAPITAL MANAGEMENT, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001346824

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 88 positions · Total reported value $9.72B · Top-10 concentration 62.7% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.4% · 15 new · 12 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.8% · Prev Value $11.51B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $9.72B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 88 equity positions with a combined reported value of $9.72B. The filing implies a focused portfolio: its ten largest positions account for 62.7% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were ASND ($2.34B), PBLS ($942.16M), PCVX ($652.90M). By sector, the heaviest allocations are Health Care 99.3%, Financials 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+1.3pp) and away from Other (-1.2pp).

Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions. The portfolio's overlap with the prior quarter was 74% of names.

The largest new positions opened in Q3 2026 were AMLX ($124.53M), VRDN ($81.79M), DBVT ($43.01M).

Of the 11 positions fully exited versus the prior quarter, the largest were BCRX ($158.27M), NUVL ($153.94M), NTLA ($76.60M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • AMLX AMYLYX PHARMACEUTICALS INC · $124.53M
  • VRDN VIRIDIAN THERAPEUTICS INC · $81.79M
  • DBVT DBV TECHNOLOGIES S A · $43.01M
  • AGEN AGENUS INC · $40.93M
  • SYRE SPYRE THERAPEUTICS INC · $33.17M
  • ANIX ANIXA BIOSCIENCES INC · $28.57M
  • GRTX ELECTRA THERAPEUTICS INC · $19.05M
  • SGMT SAGIMET BIOSCIENCES INC · $17.78M

Fully Exited (vs previous quarter)

  • BCRX BIOCRYST PHARMACEUTICALS INC · prev qtr: $158.27M
  • NUVL NUVALENT INC · prev qtr: $153.94M
  • NTLA INTELLIA THERAPEUTICS INC · prev qtr: $76.60M
  • DFTX DEFINIUM THERAPEUTICS INC · prev qtr: $70.56M
  • AKTS AKTIS ONCOLOGY INC · prev qtr: $42.36M
  • BIOA BIOAGE LABS INC · prev qtr: $40.97M
  • KPTI KARYOPHARM THERAPEUTICS INC · prev qtr: $18.73M
  • WAY WAYSTAR HLDG CORP · prev qtr: $10.87M

Insider Transactions (Form 4)

Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 164,891 $16.00 SEC filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 2,335,109 $16.00 SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 1,331,080 — SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 3,144,858 — SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 263,911 $14.92 SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 189,909 $14.23 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 107,170 $3.36 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 451,998 $3.36 SEC filing

All insider transactions →

Fund Profile

RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.

Investment Approach

Focuses on healthcare sector investments

Long-term, value-oriented strategy

Deep fundamental research and analysis

Asset Classes & Strategy

Primarily invests in public equities

Also manages private investments in healthcare companies

Concentrated portfolio approach with significant positions in healthcare companies

Key Personnel

Peter Kiernan: Founder and portfolio manager

Team of experienced investment professionals with healthcare expertise

Notable Facts

Founded in 2002

Manages approximately $16.4 billion in assets

Files SEC Form 13F for US equity positions

This profile is based on publicly available information and should not be considered as official disclosure from the firm.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased its total portfolio value by $9716.0M, with a clear focus on adding positions in biotech/healthcare (PBLS, ARTV) while selectively reducing others (SEPN), suggesting a bullish stance on innovative therapeutics but with some profit-taking. 2. Key moves: - Added: PBLS (Parabilis Medicines, +2.82% weight), ARTV (Artiva Biotherapeutics, +0.76% weight). - Reduced: SEPT (Septerna, -21.3% shares sold, weight unchanged due to price effect). 3. Portfolio structure: Highly active, concentrated in Health Care (100% of top 10), with a preference for clinical-stage biotech/pharma, indicating high-risk, high-reward appetite. 4. Per-holding one-liner: - ASND: Ascendis Pharma (growth hormone disorders). - PBLS: Parabilis Medicines (unverified, likely biotech). - PCVX: Vaxcyte (vaccine development). - RYTM: Rhythm Pharmaceuticals (obesity/rare diseases). - EWTX: Edgewise Therapeutics (muscle disorders). - TYRA: Tyra Biosciences (unverified, likely oncology). - COAG: Hemab Therapeutics (hemophilia). - NAMS: NewAmsterdam Pharma (metabolic diseases). - ARTV: Artiva Biotherapeutics (unverified, likely immuno-oncology). - SEPN: Septerna (GI disorders). 5. Style summary: Aggressive biotech investor doubling down on high-potential clinical-stage names while trimming losers.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:28

Sector Allocation

Health Care 99.3%
Financials 0.3%
Materials 0.0%
Other 0.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 10.28M $2.34B 24.11%
24.11%
Hold
2 29.18M $942.16M 9.70%
9.70%
Add
3 11.47M $652.90M 6.72%
6.72%
Hold
4 6.67M $634.78M 6.53%
6.53%
Hold
5 8.39M $340.74M 3.51%
3.51%
Hold
6 12.20M $266.78M 2.75%
2.75%
Hold
7 7.81M $240.82M 2.48%
2.48%
Hold
8 9.55M $232.26M 2.39%
2.39%
Hold
9 23.79M $220.20M 2.27%
2.27%
Add
10 5.50M $215.33M 2.22%
2.22%
Reduce
11 8.02M $208.55M 2.15%
2.15%
Hold
12 11.19M $193.36M 1.99%
1.99%
Hold
13 7.69M $193.32M 1.99%
1.99%
Hold
14 2.45M $160.39M 1.65%
1.65%
Hold
15 30.44M $148.22M 1.53%
1.53%
Add
16 7.26M $135.03M 1.39%
1.39%
Hold
17 5.27M $131.59M 1.35%
1.35%
Hold
18 1.55M $129.48M 1.33%
1.33%
Hold
19 4.28M $124.53M 1.28%
1.28%
New
20 10.13M $116.19M 1.20%
Form 4 · 4 →
1.20%
Reduce
21 1.03M $102.00M 1.05%
1.05%
Reduce
22 26.98M $99.81M 1.03%
Form 4 · 1 →
1.03%
Hold
23 12.04M $87.02M 0.90%
0.90%
Hold
24 4.50M $85.93M 0.88%
Form 4 · 1 →
0.88%
Add
25 2.21M $84.77M 0.87%
0.87%
Hold
26 3.61M $84.74M 0.87%
0.87%
Reduce
27 5.96M $81.79M 0.84%
0.84%
New
28 2.82M $74.16M 0.76%
0.76%
Reduce
29 5.05M $72.26M 0.74%
0.74%
Hold
30 12.72M $66.92M 0.69%
0.69%
Hold
31 18.75M $54.66M 0.56%
0.56%
Hold
32 667.21K $53.16M 0.55%
0.55%
Hold
33 42.75M $52.59M 0.54%
0.54%
Hold
34 2.40M $51.07M 0.53%
0.53%
Hold
35 20.06M $48.56M 0.50%
0.50%
Hold
36 10.86M $46.81M 0.48%
0.48%
Hold
37 20.99M $46.60M 0.48%
0.48%
Hold
38 3.66M $43.01M 0.44%
0.44%
New
39 4.12M $40.93M 0.42%
0.42%
New
40 9.45M $39.10M 0.40%
0.40%
Hold
41 6.46M $33.96M 0.35%
0.35%
Reduce
42 1.80M $33.17M 0.34%
0.34%
New
43 17.75M $30.36M 0.31%
0.31%
Hold
44 3.49M $28.87M 0.30%
0.30%
Hold
45 892.74K $28.57M 0.29%
0.29%
New
46 3.01M $28.54M 0.29%
0.29%
Add
47 10.81M $28.31M 0.29%
0.29%
Hold
48 8.19M $27.29M 0.28%
0.28%
Add
49 1.84M $25.79M 0.27%
0.27%
Reduce
50 6.48M $25.32M 0.26%
0.26%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 90% R 90% F1 90% (modelled on 2026-Q2; 9/10 hit)

Low-confidence forecast This fund replaces about 25% of its Top-10 each quarter and backtests at F1 74% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 74% · recall 74% · F1 74% · avg rank error 1.9 · Top-10 turnover 25%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 60% 60% 60% ASND · IMGN · PCVX · LEGN · RYTM · AVTE · INBX · CBAY · RXST · BIIB ASND · PCVX · LEGN · JANX · AVTE · RYTM · EVH · NAMS · RXST · TYRA
2024-Q2 60% 60% 60% ASND · PCVX · LEGN · JANX · AVTE · RYTM · EVH · NAMS · RXST · TYRA ASND · PCVX · JANX · LEGN · RYTM · BIIB · CLYM · RXST · RNAM · DYN
2024-Q3 70% 70% 70% ASND · PCVX · JANX · LEGN · RYTM · CLYM · BIIB · RNAM · RXST · DYN ASND · PCVX · JANX · LEGN · RYTM · RNAM · TYRA · EVH · EWTX · BIIB
2024-Q4 70% 70% 70% ASND · PCVX · JANX · LEGN · RYTM · RNAM · EVH · TYRA · BIIB · EWTX ASND · PCVX · JANX · RYTM · LEGN · EWTX · NAMS · WVE · ACLX · RNAM
2025-Q1 90% 90% 90% ASND · PCVX · JANX · RYTM · LEGN · EWTX · NAMS · ACLX · WVE · RNAM ASND · PCVX · RYTM · JANX · NAMS · ACLX · EWTX · RNAM · WVE · ETNB
2025-Q2 80% 80% 80% ASND · PCVX · RYTM · JANX · NAMS · ACLX · EWTX · RNAM · ETNB · WVE ASND · PCVX · RYTM · JANX · RNAM · ACLX · ETNB · SPRY · NAMS · SION
2025-Q3 80% 80% 80% ASND · PCVX · RYTM · JANX · RNAM · ETNB · ACLX · SPRY · NAMS · CDTX ASND · RYTM · PCVX · RNAM · CDTX · SION · ETNB · NAMS · MLYS · JANX
2025-Q4 80% 80% 80% ASND · RYTM · PCVX · RNAM · CDTX · SION · NAMS · ETNB · MLYS · JANX ASND · CDTX · RYTM · RNAM · PCVX · SION · NAMS · TYRA · WVE · MLYS
2026-Q1 70% 70% 70% ASND · CDTX · RYTM · RNAM · PCVX · SION · NAMS · TYRA · WVE · MLYS ASND · PCVX · RYTM · TYRA · SION · EWTX · NAMS · NUVL · DNTH · MLYS
2026-Q2 70% 70% 70% ASND · PCVX · RYTM · TYRA · SION · EWTX · NAMS · NUVL · DNTH · MLYS ASND · PBLS · RYTM · PCVX · SION · TYRA · EWTX · NAMS · COAG · SEPN
2026-Q3 ★ 90% 90% 90% ASND · PBLS · RYTM · PCVX · SION · TYRA · EWTX · NAMS · COAG · SEPN ASND · PBLS · PCVX · RYTM · EWTX · TYRA · COAG · NAMS · ARTV · SEPN

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings4 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-17.38%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return-0.37%vs benchmark
Barra annualised vol61.1%Model estimate
Realised vol60.6%Annualised in window
Weighted beta1.24Raw exposure
Factor / specific risk38% / 62%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)77.084.091.098.1105.110-0110-2311-16RA CAPITAL MANAGEMENT, L.P.QQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-17.38%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return-0.37%Portfolio − benchmark
Arithmetic return sum-16.64%Difference vs compounded is the cross term
Weighted raw beta1.24Weighted holding betas
Realised volatility (annualised)60.62%Daily returns in window
Barra model volatility (annualised)61.13%Factor + specific
Factor share of variance37.6%Barra factors
Specific share of variance62.4%Stock residuals
Reported value$398.8M13F long US equity

2. Return attribution

The -16.64% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -7.85% -47.2%
Momentum & Growth 3 -3.88% -23.3%
Volatility & Tail Risk 7 +13.82% 83.0%
Industry 12 +6.98% 42.0%
Specific 1 -25.70% -154.5%
Return attribution (style + industry, %)-16.1-8.1+0.0+8.1+16.1Amihud Illiquidity-1.23Beta+1.70Momentum-1.93Growth-2.49Non-linear Size+3.10Size+3.23Leverage (Downside Vol)-4.48Mid Cap-5.17Health Care+6.98Residual Volatility+7.63Turnover-8.08Skewness+8.72Kurtosis+13.97Historical Volatility-14.92
Factor Type Exposure Factor return Contribution Share of |return|
Kurtosis Style +1.86 +7.51% +13.97% 83.9%
Skewness Style -1.98 -4.39% +8.72% 52.4%
Residual Volatility Style +2.32 +3.29% +7.63% 45.9%
Health Care Industry +1.00 +6.98% +6.98% 42.0%
Size Style -1.66 -1.95% +3.23% 19.4%
Non-linear Size Style +3.07 +1.01% +3.10% 18.6%
Beta Style +0.38 +4.44% +1.70% 10.2%
Max Drawdown Style -0.68 -1.76% +1.20% 7.2%
Short-term Reversal Style +0.62 +0.87% +0.54% 3.3%
Liquidity Style +0.81 +0.36% +0.29% 1.8%
Amihud Illiquidity Style +2.75 -0.45% -1.23% -7.4%
Momentum Style +0.48 -4.00% -1.93% -11.6%
Growth Style -1.43 +1.75% -2.49% -15.0%
Leverage (Downside Vol) Style +2.61 -1.71% -4.48% -26.9%
Mid Cap Style +2.67 -1.94% -5.17% -31.1%
Turnover Style +1.68 -4.80% -8.08% -48.6%
Historical Volatility Style +1.07 -14.00% -14.92% -89.6%
Specific Specific — — -25.70% -154.5%

3. Risk attribution

Annualised volatility is 61.13%; factor risk explains 37.6% of variance and specific risk 62.4%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-67.4-33.7+0.0+33.7+67.4Skewness-1.46Liquidity+1.01Turnover+1.14Beta+1.26Growth+1.26Amihud Illiquidity+1.89Non-linear Size+2.58Size+2.97Historical Volatility+4.13Residual Volatility+5.14Leverage (Downside Vol)+5.94Health Care+6.57Mid Cap+6.76Specific+62.45
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 62.5% +38.17% 38.2%
Mid Cap Style +2.67 6.8% +4.13% 4.1%
Health Care Industry +1.00 6.6% +4.01% 4.0%
Leverage (Downside Vol) Style +2.61 5.9% +3.63% 3.6%
Residual Volatility Style +2.32 5.1% +3.14% 3.1%
Historical Volatility Style +1.07 4.1% +2.53% 2.5%
Size Style -1.66 3.0% +1.81% 1.8%
Non-linear Size Style +3.07 2.6% +1.57% 1.6%
Amihud Illiquidity Style +2.75 1.9% +1.16% 1.2%
Beta Style +0.38 1.3% +0.77% 0.8%
Growth Style -1.43 1.3% +0.77% 0.8%
Turnover Style +1.68 1.1% +0.69% 0.7%
Liquidity Style +0.81 1.0% +0.62% 0.6%
Momentum Style +0.48 0.2% +0.12% 0.1%
Kurtosis Style +1.86 -0.5% -0.31% -0.3%
Max Drawdown Style -0.68 -0.5% -0.31% -0.3%
Short-term Reversal Style +0.62 -0.8% -0.50% -0.5%
Skewness Style -1.98 -1.5% -0.89% -0.9%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-2.5-1.00.52.13.6Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.66 +2.10 -3.76
Non-linear Size +3.07 +1.68 +1.39
Mid Cap +2.67 +0.13 +2.54
Beta +0.38 +1.29 -0.91
Momentum +0.48 +0.72 -0.23
Short-term Reversal +0.62 -0.64 +1.26
Residual Volatility +2.32 -0.40 +2.72
Historical Volatility +1.07 +0.86 +0.21
Liquidity +0.81 +0.11 +0.70
Amihud Illiquidity +2.75 +1.16 +1.60
Turnover +1.68 +0.21 +1.48
Growth -1.43 +0.58 -2.01
Leverage (Downside Vol) +2.61 +0.14 +2.47
Skewness -1.98 +0.24 -2.22
Kurtosis +1.86 +0.21 +1.65
Max Drawdown -0.68 -0.08 -0.60

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Health Care 100.0% 1.7% -17.75% +8.29% +24.98% -0.45% -25.59% -17.89%
Total +23.98% +15.39% -41.43% -2.05%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
NAMS NEWAMSTERDAM PHARMA COMPANY Health Care 58.24% -19.98% -11.64% Hold
TSHA TAYSHA GENE THERAPIES INC Health Care 37.16% -16.63% -6.18% Add
SGMT SAGIMET BIOSCIENCES INC Health Care 4.46% +2.53% +0.11% New
PTN PALATIN TECHNOLOGIES INC Health Care 0.14% -30.95% -0.04% Hold
Contribution rank Symbol Sector Weight Return Contribution
1 SGMT Health Care 4.46% +2.53% +0.11%
2 PTN Health Care 0.14% -30.95% -0.04%
3 TSHA Health Care 37.16% -16.63% -6.18%
4 NAMS Health Care 58.24% -19.98% -11.64%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -17.38%, versus -17.01% for the QQQ synthetic benchmark — an excess of -0.37%.
  2. Return attribution: the largest positive style/industry contributions came from Kurtosis +13.97%, Skewness +8.72%, Residual Volatility +7.63%; the largest drags came from Historical Volatility -14.92%, Turnover -8.08%, Mid Cap -5.17%. Specific (stock-level) return contributed -25.70%.
  3. Risk attribution: Barra model volatility is 61.13% annualised; factor risk explains 38% of variance and specific risk 62%. The largest factor risk sources are Mid Cap 6.8%, Health Care 6.6%, Leverage (Downside Vol) 5.9%.
  4. Style tilt: size -1.66, momentum +0.48, volatility +1.07, liquidity +0.81; the weighted raw beta is 1.24. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.39% and interaction -41.43%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did RA CAPITAL MANAGEMENT, L.P. buy in 2026-Q3?

In its 2026-Q3 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 88 equity positions worth $9.72B in aggregate; its largest disclosed positions were ASND ($2.34B), PBLS ($942.16M), PCVX ($652.90M).

How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?

RA CAPITAL MANAGEMENT, L.P. reported $9.72B of long equity holdings across 88 positions as of 2026-Q3. Top-10 holdings account for 62.7% of reported value.

What is RA CAPITAL MANAGEMENT, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ra-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →